H1 Receptor Antagonist

Phase 3Small molecule

H1 Receptor Antagonist is one of 87 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerActive, not recruiting

Ovarian CancerActive, not recruiting

Non-Small Cell Lung Cancer (NSCLC)Active, not recruiting

Lung Neoplasm MalignantRecruiting

Non-Small Cell Lung CancerPhase 3

Active, not recruiting

Ovarian CancerPhase 3

Active, not recruiting

Non-Small Cell Lung Cancer (NSCLC)Phase 3

Active, not recruiting

Lung Neoplasm MalignantPhase 2

Recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

H1 Receptor Antagonist

Merck & Co.

Phase 3

3 2

Yervoy

Bristol-Myers Squibb

Preclinical

31 3

Gemzar

GGynecologic Oncology Group

Preclinical

72 4

PORTRAZZA

Eli Lilly

Preclinical

8 5

Lenvima

Eisai

Preclinical

6 6

Imjudo

AstraZeneca

Preclinical

5 7

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 8

Tyrosine Kinase Inhibitor

Pfizer

Preclinical

2 9

Treatment

GSK

Preclinical

1 10

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

Phase 3Active, not recruiting

Non-Small Cell Lung Cancer (NSCLC)

NCT06305754

Q1 2032

Phase 2Recruiting

Lung Neoplasm Malignant

NCT06788912

Q4 2032

Phase 3Recruiting

Ovarian Cancer

NCT06824467

Clinical

Trials by Indication[1]

Ovarian Cancer1 trial

A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer (TroFuse-022/ENGOT-ov84/GOG-3103)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06824467·770 enrolled

Non-small Cell Lung Cancer (NSCLC)1 trial

A Randomized, Open-label, Phase 3 Study of MK-2870 vs. Platinum Doublets in Participants With EGFR-mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06305754·520 enrolled

Lung Neoplasm Malignant1 trial

KEYMAKER-U01 Substudy 01E: A Phase 2 Umbrella Study With Rolling Arms of Investigational Agents With or Without Chemotherapy in Combination With Pembrolizumab in Treatment of Participants With Newly Diagnosed Resectable Stages II-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT06788912·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for H1 Receptor Antagonist. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — H1 Receptor Antagonist compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for H1 Receptor Antagonist. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Merck & Co.

H1 Receptor Antagonist

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2030

Q1 2032

Q4 2032

Trials by Indication[1]

Ovarian Cancer1 trial

Non-small Cell Lung Cancer (NSCLC)1 trial

Lung Neoplasm Malignant1 trial

References

Drug Info

Quick Facts

Related News